A detailed history of Dodge & Cox transactions in Incyte Corp stock. As of the latest transaction made, Dodge & Cox holds 15,276,093 shares of INCY stock, worth $1.09 Billion. This represents 0.61% of its overall portfolio holdings.

Number of Shares
15,276,093
Previous 15,279,343 0.02%
Holding current value
$1.09 Billion
Previous $926 Million 9.02%
% of portfolio
0.61%
Previous 0.58%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$57.33 - $68.61 $186,322 - $222,982
-3,250 Reduced 0.02%
15,276,093 $1.01 Billion
Q2 2024

Aug 13, 2024

SELL
$51.18 - $63.75 $7 Million - $8.71 Million
-136,700 Reduced 0.89%
15,279,343 $926 Million
Q1 2024

May 14, 2024

SELL
$56.55 - $66.59 $38.1 Million - $44.9 Million
-674,378 Reduced 4.19%
15,416,043 $878 Million
Q4 2023

Feb 15, 2024

SELL
$52.16 - $64.19 $17 Million - $20.9 Million
-325,690 Reduced 1.98%
16,090,421 $1.01 Billion
Q3 2023

Nov 14, 2023

SELL
$57.77 - $65.93 $165 Million - $189 Million
-2,861,849 Reduced 14.85%
16,416,111 $948 Million
Q2 2023

Aug 14, 2023

SELL
$60.95 - $75.51 $3.31 Million - $4.1 Million
-54,350 Reduced 0.28%
19,277,960 $1.2 Billion
Q1 2023

May 12, 2023

SELL
$70.23 - $86.01 $2.15 Million - $2.63 Million
-30,625 Reduced 0.16%
19,332,310 $1.4 Billion
Q4 2022

Feb 14, 2023

SELL
$67.18 - $84.11 $28.9 Million - $36.2 Million
-430,465 Reduced 2.17%
19,362,935 $1.56 Billion
Q3 2022

Nov 10, 2022

SELL
$66.18 - $82.86 $18.2 Million - $22.7 Million
-274,445 Reduced 1.37%
19,793,400 $1.32 Billion
Q2 2022

Aug 12, 2022

BUY
$66.18 - $83.18 $133 Million - $167 Million
2,007,555 Added 11.12%
20,067,845 $1.52 Billion
Q1 2022

May 13, 2022

BUY
$66.02 - $79.71 $92.6 Million - $112 Million
1,402,704 Added 8.42%
18,060,290 $1.43 Billion
Q4 2021

Feb 14, 2022

BUY
$63.34 - $74.11 $11.5 Million - $13.4 Million
181,150 Added 1.1%
16,657,586 $1.22 Billion
Q3 2021

Nov 15, 2021

BUY
$68.67 - $84.02 $198 Million - $242 Million
2,878,900 Added 21.17%
16,476,436 $1.13 Billion
Q2 2021

Aug 13, 2021

BUY
$79.87 - $87.53 $741 Million - $812 Million
9,280,144 Added 214.95%
13,597,536 $1.14 Billion
Q1 2021

May 14, 2021

BUY
$76.02 - $100.5 $81 Million - $107 Million
1,064,862 Added 32.74%
4,317,392 $351 Million
Q4 2020

Feb 11, 2021

SELL
$80.74 - $97.7 $2.94 Million - $3.56 Million
-36,401 Reduced 1.11%
3,252,530 $283 Million
Q3 2020

Nov 13, 2020

SELL
$85.07 - $109.69 $32.7 Million - $42.2 Million
-384,819 Reduced 10.47%
3,288,931 $295 Million
Q2 2020

Aug 13, 2020

SELL
$74.18 - $108.93 $23.7 Million - $34.7 Million
-318,850 Reduced 7.99%
3,673,750 $382 Million
Q1 2020

May 14, 2020

BUY
$63.18 - $85.97 $14.8 Million - $20.1 Million
233,850 Added 6.22%
3,992,600 $292 Million
Q4 2019

Feb 13, 2020

SELL
$73.04 - $95.72 $11.2 Million - $14.7 Million
-153,525 Reduced 3.92%
3,758,750 $328 Million
Q3 2019

Nov 13, 2019

SELL
$72.82 - $86.52 $21.6 Million - $25.7 Million
-296,900 Reduced 7.05%
3,912,275 $290 Million
Q2 2019

Aug 13, 2019

SELL
$73.52 - $88.7 $3.39 Million - $4.1 Million
-46,175 Reduced 1.09%
4,209,175 $358 Million
Q1 2019

May 14, 2019

BUY
$63.56 - $88.17 $969,290 - $1.34 Million
15,250 Added 0.36%
4,255,350 $366 Million
Q4 2018

Feb 14, 2019

BUY
$58.5 - $69.94 $248 Million - $297 Million
4,240,100 New
4,240,100 $270 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.8B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Dodge & Cox Portfolio

Follow Dodge & Cox and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dodge & Cox, based on Form 13F filings with the SEC.

News

Stay updated on Dodge & Cox with notifications on news.